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GLYCOGEN SYNTHASE KINASE 3 IS IS REQUIRED FOR OPTIMAL AKT
ACTIVATION
Debora S. Bruno, M.D.
Advisor: Gordon B. Mills, M.D., Ph.D.

The phosphatidylinositol 3-kinase (PI3K) pathway, through its major effector node AKT, is
critical for the promotion of cell growth, division, motility and apoptosis evasion. This
signaling axis is therefore commonly targeted in the form of mutations and amplifications in
a myriad of malignancies. Glycogen synthase kinase 3 (GSK3) was first discovered as the
kinase responsible for phosphorylating and inhibiting the activity of glycogen synthase,
ultimately antagonizing the storage of glucose as glycogen. Its activity counteracts the
effects of insulin in glucose metabolism and AKT has long been recognized as one of the
key molecules capable of phosphorylating GSK3 and inhibiting its activity. However, here
we demonstrate that GSK3 is required for optimal phosphorylation and activation of AKT in
different malignant cell lines, and that this effect is independent of the type of growth factor
stimulation and can happen even in basal states. Both GSK3α and GSK3β isoforms are
necessary for AKT to become fully active, displaying a redundant role in this setting. We
also demonstrate that this effect of GSK3 on AKT phosphorylation and full activation is
dependent on its kinase activity, since highly specific inhibitors targeting GSK3 catalytic
activity also promote a reduction in phosphorylated AKT. Analysis of reverse phase protein
array screening of MDA-MB-231 breast cancer cells treated with RNA interference
targeting GSK3 unexpectedly revealed an increase in levels of phosphorylated MAPK14
(p38). Treatment with the selective p38 inhibitor SB 202190 rescued AKT activation in that
cell line, corroborating the importance of unbiased proteomic analysis in exposing crosstalks between signaling networks and demonstrating a critical role for p38 in the regulation
of AKT phosphorylation.
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INTRODUCTION:
1.

The Phosphatidylinositol 3-kinase (PI3K) pathway

The phosphatidylinositol 3-kinases are members of a family of intracellular lipid kinases
that phosphorylate the 3’-hydroxyl group of the inositol ring of phosphatidylinositides
(Engelman et al., 2006). The phosphorylated 3’-hydroxyl group acts as an intracellular
second messenger, an anchor to proteins possessing pleckstrin homology (PH) domains
(Isakoff et al., 1998; Lemmon and Ferguson, 2000), such as AKT and phosphoinositidedependent kinase 1 (PDK1). PtdIns(3,4,5)P3 can activate AKT (also known as Protein
Kinase B or PKB) by causing a translocation to the membrane of AKT itself and of its
upstream Thr308–directed protein kinase, PDK1 (Alessi et al., 1997b; Stephens et al., 1998).
Therefore, following activation of the insulin receptor and other receptor tyrosine kinases
that respond to a variety of growth factors, PI3K ultimately orchestrates the recruitment and
activation of one of the most important molecules in cell signaling. As such, AKT is
responsible for controlling growth, metabolism, proliferation, and apoptosis evasion.
Understandably, the PI3K pathway is affected by mutations and amplifications in a variety
of cancers (Yuan and Cantley, 2008), constituting a desirable target for new therapeutic
agents. However, altering the function of the effector nodes in this pathway for therapeutic
reasons requires a vast understanding of the possible regulatory and intricate feedback loops
that can be offset by such therapeutic approaches.
1.1. Classes of phosphatidylinositol 3-kinases
Three different classes (I-III) of phosphatidylinositol 3-kinases exist, which differ based on
their substrate preference and sequence homology (Engelman et al., 2006).
Class I PI3Ks primarily generate PtdIns(3,4,5)P3 from PtdIns(4,5)P2. Class IA and IB
PI3Ks differ primarily on their regulatory subunits. Class IA PI3Ks are heterodimers
consisting of a regulatory subunit (p85α, p85β or p55γ) and a catalytic subunit (p110)
(Fruman et al., 1998). Each of the regulatory subunits of the Class I of PI3Ks is encoded by
1

a distinct gene (PIK3R1, PIK3R2 and PIK3R3, respectively). The basic structure of the p85
regulatory units contains 2 Src-homology 2 (SH2) domains that flank one p110-binding
domain. Through their SH2 domains, the p85 regulatory subunits bind to phosphorylated
tyrosine residues on activated receptor tyrosine kinases (RTKs) or adaptor molecules such as
insulin receptor substrate 1 (IRS1).

This binding is fundamental for the relief of the

inhibitory action that p85 exerts on the p110 catalytic subunit of the PI3K molecule (Yu et
al., 1998). Three different genes encode the p110 catalytic subunit isoforms p110α, p110β
and p110δ (PIK3CA, PIK3CB and PIK3CD, respectively) (Fruman et al., 1998). While
p110α and p110β are ubiquitously expressed, the p110δ subunit is predominanlty expressed
in leukocytes (Engelman et al., 2006). The p110 catalytic subunit contains 5 distinct
domains: an N-terminal p85-binding domain, a GTPase Ras-binding domain (RBD), a C2
domain, a PIK homology domain and the catalytic domain located in the C-terminal end of
the subunit. Class IA PI3Ks are activated by the growth factor RTKs. While the insulin and
insulin-like growth factor 1 (IGF-1) receptors utilize the IRS family of adaptor molecules to
recruit Class IA PI3Ks to the plasma membrane and trigger their actvivity, other RTKs such
as the epidermal growth factor receptor (EGFR) recruit Class IA PI3K directly. The small
GTPase Ras can also directly activate Class IA PI3K by interaction with the RBD domain of
the p110 catalytic subunit.
Class IB PI3Ks have a p101 regulatory subunit and a p110γ catalytic subunit. Since class IB
PI3Ks do not possess a p85 regulatory subunit, they are typically not regulated by RTKs,
and rather activated by the G-protein-coupled receptors.
Class II PI3Ks consist of a single p110-like catalytic subunit, in three different isoforms
(PI3K C2α, β and γ). Although it is generally assumed that class II PI3Ks can phosphorylate
both PtdIns and PtdIns(4)P in vitro, they seem to have a preferential activity for PtdIns,
transforming it into PtdIns(3)P. In vivo studies also suggest that PtdIns(3)P might be the
most abundant product generated by this class of PI3K (Falasca and Maffucci, 2007).
Nevertheless, there is yet a considerable lack of information regarding the function and
regulation of this class of PI3Ks.
Class III is represented solely by the mammalian homolog of the vacuolar protein-sorting
2

defective 34 (Vps34) molecule, first identified in Saccharomyces cerevisiae. Vps34 is
indeed the only PI3K present in yeast. PtdIns is also the solo substrate of this class of PI3K
identified, and accordingly, the only product it generates is PtdIns(3)P. In both yeast and
mammalian cells, Vps34 is required for the induction of autophagy during nutrient
deprivation (Backer, 2008). However, as Vps34 has also been implicated in the positive
regulation of mTOR/raptor signaling through nutrient sensing (Byfield et al., 2005;
Nobukuni et al., 2005), its role in autophagy might be context-dependent. More recently, Src
has been demonstrated to phosphorylate and activate Vps34, in mammalian cells, leading to
cellular transformation (Hirsch et al., 2010).
1.2. PI3K pathway and human disease
The PI3K pathway is at the center of growth and metabolism control, and alterations of its
signaling are underlying causes of two of the most prominent diseases in developed
countries: cancer and Type II Diabetes Mellitus.
1.2.1. PI3K pathway and Type II Diabetes Mellitus
The PI3K pathway has a central role in mediating the effects of insulin on cellular
metabolism. Activation of this pathway by insulin and IGF leads to increased glucose
uptake, as well as glycogen and protein synthesis. Therefore, Type II Diabetes Mellitus,
which is characterized by insulin insensitivity, is associated with a decreased response of
this pathway to insulin stimulation (Luo et al., 2006), and subsequent decrease in glucose
utilization and storage. The class IA p110α catalytic subunit seems to be the key mediator of
insulin metabolic actions in the liver. Mice with hepatic knockout of the p110α subunit
exhibit impaired insulin sensitivity, glucose intolerance, and increased gluconeogenesis
(Sopasakis et al., 2010). Interestingly, with the advance of clinical trials looking at the
potential anti-cancer effects of drugs targeting this pathway, insulin resistance has become a
potential toxicity as well as a pharmacodynamic marker of PI3K inhibition (Courtney et al.,
2010). It seems though that with the development of inhibitors targeting specific p110
isoforms, it might be possible to selectively avoid the development of insulin resistance if
only p110β or δ isoform inhibition is provided.
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Also interesting is the finding that the p85 subunit’s dosage might interfere with the optimal
activity of the p110 catalytic subunit. Studies utilizing transgenic mice lacking either p85α
or p85β subunits have consistently demonstrated a paradoxical enhancement in insulin
sensitivity due to increased PI3K signaling downstream of the IRS proteins (Mauvais-Jarvis
et al., 2002; Terauchi et al., 1999). Existing in greater concentration than the p110 subunits,
free p85 can actually interfere with the binding of the heterodimeric p85/p110 complexes to
IRS1 by sequestering this adaptor protein into cytoplasmic foci (Luo et al., 2005), and
therefore function as a hindrance to PI3K activation.
1.2.2. PI3K pathway and Cancer
Inappropriate signaling through the PI3K pathway has been undoubtedly one of the most
frequently noted occurrences in human cancer. In 1985, it was demonstrated that the
oncogenic polyoma middle T antigen, through its interaction with pp60c-src, was able to
activate PI3K to generate the second messenger PtdIns(3,4,5)P3 (Whitman et al., 1985).
Later on it was made clear that the single most important step in the oncogenic capabilities
of the middle T antigen of polyomavirus was the generation of PtdIns(3,4,5)P3 (Ling et al.,
1992). The PI3K pathway has every major node targeted by mutations or amplifications in a
wide variety of solid tumors. Receptor tyrosine kinases upstream of PI3K, the p110α
catalytic subunit of PI3K, its downstream major effector kinase AKT, and its negative
regulator, the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10
(PTEN) are all frequently altered in cancer (Yuan and Cantley, 2008).
Following the activation and therefore tyrosine phosphorylation of cytoplasmic tails of
RTKs, only a small fraction of the available PI3K is recruited to the plasma membrane.
Therefore, even slight increments in the engagement of these receptors can lead to manyfold increases in PI3K activity (Yuan and Cantley, 2008). The epidermal growth factor
receptor tyrosine kinase family consists of four members: EGFR (HER1, erbB1), HER2
(erbB2, HER2/neu), HER3 (erbB3) and HER4 (erbB4). EGFR is amplified or mutated in a
variety of malignant histologies and the use of tyrosine kinase inhibitors and monoclonal
antibodies targeting EGFR has proved to be beneficial in several clinical settings. As an
4

example, in non-small cell lung cancer (NSCLC), deletions in exon 19 and L858R point
mutations in exon 21 were reported to be associated with responses to treatment with
tyrosine kinase inhibitors targeting EGFR (Lynch et al., 2004; Paez et al., 2004). On the
other hand, HER2 has tumorigenic capabilities through overexpression alone (Moasser,
2007). Gene amplification and transcriptional deregulation lead to HER2 overexpression in
approximatley 20 to 25% of ovarian and breast cancers, confering a more aggressive
biological behavior (Slamon et al., 1989). HER2 overexpression is also seen in subsets of
gastric, esophageal and endometrial cancer, also associated with worse prognostic features
(Moasser, 2007). However, the discovery of this biological marker has also allowed the
development of drugs that had profound impact in the survival in a subset of cancer patients
whose tumors harbor HER2 overexpression. The use of the monoclonal antibody targeting
HER2, trastuzumab, in addition to chemotherapy, has proved to increase the overall survival
of breast cancer patients who are candidates for this therapy (Slamon et al., 2001). Also,
dual inhibition of the EGFR and HER2 tyrosine kinases by the small molecule lapatinib has
proved beneficial in women with metastatic breast cancer overexpressing HER2 that have
developed resistance to trastuzumab (Geyer et al., 2006). Another most critical RTK
involved in cancer cell signaling is the insulin-like growth factor receptor (IGF-1R). This
receptor belongs to the insulin receptor (IR) family, and these two receptors, while highly
homologous in their TK domains, differ considerably in their functions (Larsson et al.,
2005).

While IGF-1R regulates mostly cellular proliferation, differentiation, apoptosis

evasion and motility, IR is mostly responsible for the control of glucose uptake and
metabolism (Larsson et al., 2005). Following ligand binding, phosphorylation of the critical
tyrosine residues Y1131, 1135 and 1136 release the auto-inhibitory conformation of the
activation loop and the catalytic active TK goes on to phosphorylate adaptor proteins such as
the insulin receptor substrates 1-4 (IRS 1-4) and Shc (Larsson et al., 2005). As with HER2,
IGF1R does not appear to be mutated in cancers (Maki, 2010), while overexpression of this
receptor has been demonstrated across a wide variety of human carcinomas of glandular and
transitional cell origin, including breast, ovarian, endometrial, gastric, pancreatic, colon,
lung and prostate carcinomas, as well as transitional cell carcinomas of the bladder (Ouban
et al., 2003). In lung cancer, IGF1-R protein expression is higher in the squamous histology,
and correlated with EGFR expression (Dziadziuszko et al., 2010). Interestingly though, a
high IGF1R gene copy number harbors a positive prognostic value (Dziadziuszko et al.,
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2010).
The most prevalent mutations in the PI3K pathway are the activating mutations in PIK3CA,
the gene encoding the p110α catalytic subunit of PI3K, and inactivating mutations in the
PTEN tumor-suppressor gene. PIK3CA has been found mutated in breast, endometrial,
colorectal, urinary tract and ovarian cancers (Yuan and Cantley, 2008). The majority of
these somatic mutations lie in two hotspot regions, encoding for the central helical domain
and the carboxy-terminal kinase domain of the molecule, and confering constitutive kinase
activity (Yuan and Cantley, 2008). In mammary epithelial cells, expression of p100α
mutants has been shown to promote a variety of changes associated with a malignant
phenotype, including growth factor-independent proliferation, colony growth in soft-agar,
and protection from anoikis (Isakoff et al., 2005). In contrast to p110α, no oncogenic
mutations have been found in any of the other class I PI3K catalytic subunits.
PTEN, a dual lipid and protein phosphatase, targets primarily the main second messenger
for the class I PI3K pathway, PtdIns(3,4,5)P3, creating PtdIns(4,5)P2 and relinquishing the
activation of the main downstream effectors of PI3K, namely AKT, PDK1 and Rac1/cdc42
(Blanco-Aparicio et al., 2007). The loss of PTEN leads to constitutively high levels of PIP3,
which are increased upon growth factor stimulation. Ultimately, PIP3 induction will lead to
increased cell size, enhanced survival and cell cycle progression (Keniry and Parsons, 2008).
PTEN is mutated or lost in both heritable and spontaneous cancers (Yuan and Cantley,
2008). The gene that encodes PTEN is located on chromossome 10q23, and germline
nonsense and missense mutations that disrupt its phosphatase domain are responsible for
Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an
elevated risk for tumors of the breast, thyroid and skin (Liaw et al., 1997). Somatic PTEN
alterations are commonly seen in many sporadic tumor types, such as breast, prostate and
endometrial cancers, melanomas and glioblastomas (more than 70% of GBMs harbor PTEN
loss of heterozygozity) (Hollander et al., 2011). PTEN dosage has also been shown to
correlate with an increased susceptibility for tumor development in mice, which suggests
PTEN to be haploinsufficient. Indeed, in non-small cell lung cancer, decreased PTEN
expression caused by epigenetic changes seems to be more prevalent than actual mutations
or deletions of the gene (Hollander et al., 2011).
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The three known AKT isoforms are derived from distinct genes (AKT1 from PKBα, AKT2
from PKBβ and AKT3 from PKBγ) and share more than 80% of sequence identity (Liao and
Hung, 2010). Knockout mice studies have unveiled a prominent role for AKT1 in the
regulation of apoptosis, AKT2 in the regulation of glucose homeostasis and AKT3 in brain
development (Gonzalez and McGraw, 2009). Recent work exploring the differential activity
of the PHLLPs (PH domain leucine-rich repeat phosphatases) has uncovered an intriguing
differential regulation of downstream AKT targets by the different AKT isoforms (Brognard
et al., 2007). For example, while GSK3α was specifically regulated by AKT2, GSK3β was
regulated by all three AKT isoforms. As expected, overexpression of the AKT isoforms,
dependent or not on gene amplification, has been reported in multiple cancers, including
pancreatic, ovarian, gastric, colorectal, head and neck and breast cancers, as well as
melanomas (Gonzalez and McGraw, 2009; Yuan and Cantley, 2008). Interestingly though,
even as we see multiple members of this pathway being targeted by germline or somatic
mutations, functional mutations of the three AKT isoforms are not commonly seen. This
seems a counterintuitive observation, as AKT represents a key node in the PI3K pathway. In
2007, a unique mutation in the PH domain of AKT1 (E17K) was identified in breast,
colorectal and ovarian clinical tumor specimens (8%, 6% and 2%, respectively) (Carpten et
al., 2007). This mutation was mutually exclusive with respect to mutations in PIK3CA and
complete loss of PTEN protein expression. In vitro experiments demonstrated that in the
absence of serum, the E17K mutation led to an increase in AKT1 localization to the plasma
membrane and subsequent phosphorylation. The E17K mutation alone was sufficient to
transform cells in culture and to induce leukemia in mice (Carpten et al., 2007), suggesting
that it may play a crucial role in cancer development. The molecular mechanism underlying
E17K oncogenesis seems to reside in a broadened lipid selectivity that allows high-affinity
binding of AKT1 to PtdIns(4,5)P2 (Landgraf et al., 2008).

Subsequent studies have

confirmed the presence of this mutation in a small subset of breast, colorectal, lung,
endometrial and prostate cancers (Askham et al., 2010; Bleeker et al., 2008; Boormans et al.,
2010; Kim et al., 2008; Malanga et al., 2008; Shoji et al., 2009). A second AKT1 point
mutation (E49K) has been discovered in a small percentage of bladder tumors, resulting in
elevated phosphorylation only of the Ser473 residue and much weaker transforming
capabilities in vitro (Askham et al., 2010). An also rare, but functionally relevant E17K
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mutation has been identified in the AKT3 isoform in melanoma (Davies et al., 2008).
2. AKT
2.1. Structure of AKT
The AKT molecule is composed by a central kinase domain flanked by an N-terminal
pleckstrin homology (PH) domain and a carboxyl-terminal regulatory domain that contains
the hydrophobic motif (HM) (Hanada et al., 2004). This hydrophobic motif is characteristic
of the AGC (for protein kinases A, G and C) kinases, which include AKT, p70 ribosomal S6
kinase and the serum-glucocorticoid-inducible kinase (SGC). Thr308 and Ser473 residues,
targets of phosphorylation for the full activation of AKT1 catalytic activity, are located on
the molecule’s catalytic and HM domains, respectively (Liao and Hung, 2010).
2.2. Functional Roles of AKT
AKT orchestrates several signaling changes that ultimately can be described as hallmarks of
malignant neoplastic transformation, such as evasion of apoptosis, limitless replicative
potential, sustained angiogenesis, and tissue invasion (Hanahan and Weinberg, 2000)
(Figure 2.1).
AKT inhibits apoptosis by inactivating several pro-apoptotic proteins and activating antiapoptotic ones. For instance, AKT is able to phosphorylate the Bcl-2 family member BAD
at Ser136 and effectively block BAD-induced cell death (Datta et al., 1997), by permanently
disrupting the BAD-Bcl-2 and BAD-Bcl-xL complex formation. AKT also is able to prevent
translocation of another pro-apoptotic BCL-2 family member, BAX, from the cytoplasm to
the mitochondria (Tsuruta et al., 2002). By phosphorylating FKHR1, a member of the
Forkhead family of transcription factors, AKT induces its binding to 14-3-3 proteins in the
cytosol, preventing its nuclear localization (Brunet et al., 1999). As a consequence, FKHR1dependent transcription of the pro-apoptotic genes Bim and FasL is suppressed. In addition,
AKT can phosphorylate and inactivate pro-caspase 9 at Ser196 (Cardone et al., 1998) and
promote p53 degradation by phosphorylating Mdm2 and increasing its ability to ubiquitinate
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p53 (Ogawara et al., 2002). AKT can also trigger activation of nuclear factor-kappa B (NFκB), a master regulator of cellular survival functions, by activating IKK (Inhibitor of Kappa
B Kinase) (Salminen and Kaarniranta, 2010).
AKT activation mediates cell cycle progression. By phosphorylating and inactivating GSK3,
AKT allows for cyclin D1 and c-Myc, both downstream targets of GSK3, to remain free
from ubiquitination and degradation and positively regulate G1/S cell cycle progression
(Liang and Slingerland, 2003). AKT may also, through phosphorylation, inactivate the
cyclin-dependent kinase inhibitors p21cip1 and p27 kip1.
AKT is required for cell migration/motility in different organisms. One of its substrates,
Girdin/APE (AKT-phosphorylation enhancer) is an actin binding protein that is essential for
the development of stress fibers and lamelipodia. By phosphorylating Girdin at Ser1416,
AKT allows for its accumulation at the leading edge of migrating cells (Enomoto et al.,
2005). In glioma cells, aberrant PI3K/AKT signaling leads to abnormalities in both cell
proliferation and migration (Lefranc et al., 2005). AKT, through the activation of NF-κB
(Kim et al., 2001), is also able to promote the production of matrix metalloproteinase-9
(MMP-9), resulting in the destruction of extra-cellular matrix compounds and cell
invasiveness.
The PI3K/AKT pathway is an essential effector for the vascular endothelial growth factor
receptor (VEGFR)-mediated angiogenesis. Besides VEGF, several other endothelial cell
stimuli, including angiopoietin-1, hepatocyte growth factor and fluid shear stress also
activate PI3K-AKT signaling, emphasizing the importance of this signaling pathway for
endothelial cell viability (Shiojima and Walsh, 2002). Sustained AKT activation in
endothelial cells has been demonstrated to induce the formation of enlarged,
hyperpermeable blood vessels in non-tumor tissue (Phung et al., 2006). For instance, the
production of nitric oxide, a pivotal regulator of vascular remodeling and angiogenesis, is
known to be mediated by AKT, which phosphorylates the endothelial nitric oxide synthase
(eNOS), enhancing its sensitivity to Ca2+ (Dimmeler et al., 1999).
As the major effector node of the PI3K signaling pathway, AKT’s role in cell metabolism is
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quite remarkable: it regulates glucose transport, the synthesis of both protein and glycogen,
and suppresses gluconeogenesis (Whiteman et al., 2002). Ultimately, it mediates the effects
of insulin signaling in promoting cell growth. Constitutively active AKT induces glucose
uptake into adipocytes in the absence of insulin by stimulating translocation of the glucose
transporter 4 (GLUT4) to the plasma membrane (Cong et al., 1997; Kohn et al., 1996). It
also promotes glycogen synthesis by phosphorylating and inhibiting the activity of glycogen
synthase kinase 3 (GSK3). GSK3 is one of the kinases responsible for phosphorylating and
hindering the activity of glycogen synthase, which adds activated glucosyl groups to
growing polysaccharide chains – the final step in glycogen sythesis. GSK3 phosphorylates
and inhibits eIF2B (eukaryotic initiation factor 2B), and since eIF2B is required for the
recycling of eIF2, a factor necessary for all cytoplasmic translation initiation events, AKT
promotes protein synthesis by phosphorylating GSK3 and inhibiting its activity (Proud,
2006). On the other hand, mTOR is a known regulator of both cell growth and cell
proliferation, which are coordinated by at least two of its downstream targets: S6K1 and 4EBP1. Ribosomal protein S6 kinases and proteins promote the initiation and elongation
phases of translation, while 4E-BP1 binds to eIF4E and prevents the formation of eIF4E
complexes needed for translation initiation (Averous and Proud, 2006). By phosphorylating
S6K and 4E-BP1, mTORC1 activates and inhibits, respectively, these downstream targets,
leading to an increase in protein synthesis. Insulin regulates mTORC1 signaling through the
TSC1 (tuberous sclerosis complex 1)-TSC2 protein complex: this normally acts as a
GTPase-activating complex toward the small G protein Rheb (Ras homolog enriched in
brain), directly upstream of mTORC1 (Tee et al., 2003). By directly phosphorylating TSC2,
AKT destabilizes TSC2 and disrupts its interaction with TSC1,
activity to remain intact (Inoki et al., 2002).
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allowing for the Rheb

Figure 2.1. AKT and its targets. AKT commands several signaling events that lead to
malignant neoplastic transformation by acting upon a variety of substrates. Here we
illustrate a few of those substrates that have been heighlighted in the text. The green arrows
indicate activation/promotion and the black interrupted bars indicate inactivation/inhibition.
2.3. AKT phosphorylation and activation
The first indication that AKT plays a role in oncogenesis derived from the isolation of the
transforming retrovirus AKT8, from an AKR mouse T-cell lymphoma (Staal et al., 1977).
Subsequently it became clear that the oncogenic features of v-akt were related to its
myristylation and differential subcellular localization: 40% of v-akt was found to be located
at the plasma membrane, 30% at the nucleus with only 30% left at the cytoplasm of infected
cells, whereas 90% of c-akt was located in the cytosol (Ahmed et al., 1993). Later on it was
demonstrated that membrane-associated, but not cytosolic AKT, isolated from growth-factor
stimulated hematopoietic cells, was catalytically active (Zhang and Vik, 1997), and that the
PH domain of AKT was essential for its translocation to the plasma membrane (Bellacosa et
al., 1998). The activity of AKT in mammalian cell lines was demonstrated to be controlled
by the reversible phosphorylation of serine and threonine residues of that molecule,
following either stimulation by serum or inhibition of protein phosphatase 2A (PP2A)
activity (Andjelkovic et al., 1996). The identity of one of the kinases responsible for its
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activation did not remain elusive for long. PDK1 was purified as one of the kinases that
mediated the activation of AKT by insulin and growth factors (Alessi et al., 1997b),
phosphorylating it at Thr308 (for AKT1) in the presence of lipid vesicles containing
PtdIns(3,4,5)P3 or PtdIns(3,4)P2. The identity of the second kinase(s), PDK2, responsible
for targeting Ser473 (in AKT1), however, has been a matter of much investigation and
debate. It is however recognized that full activation of AKT is a multi-step process that
results in the sequential phosphorylation of the Thr308 and Ser473 residues, in this order
(Figure 2.2). Point mutants of those sites that prevent phosphorylation (T308A and S473A)
show little activity, whereas phosphorylation-mimicking mutants (T308D and S473D) show
constitutive kinase activity (Liao and Hung, 2010).
The catalytic site of PDK1 is located in its N-terminal domain, while its C-terminus contains
the PH domain that interacts at a high affinity with PtdIns(3,4,5)P3 and one of its immediate
breakdown products, PtdIns(3,4)P2. The binding to the plasma membrane is necessary for
PDK1 to get into proximity to AKT and phosphorylate it, as experiments in which the PH
domains of those molecules have been deleted demonstrate (Alessi et al., 1997a). However,
PDK1 activity is not dependent on its interaction with the plasma membrane. This kinase is
found constitutively phosphorylated and active, independent of growth factor stimulation
(Alessi et al., 1997a). PDK1 possesses the intrinsic ability to phosphorylate its own T-loop
residue Ser241 (Mora et al., 2004).
In certain contexts, several kinases, including PDK1, ataxia telangiectasia mutated (ATM),
integrin-linked kinase (ILK), protein kinase C Beta II, and even AKT itself, have been
implicated as PDK2, responsible for the phosphorylation of Ser473 (Balendran et al., 1999;
Chan and Tsichlis, 2001; Kawakami et al., 2004; Persad et al., 2001; Toker and Newton,
2000; Viniegra et al., 2005). Later on, the identity of the hydrophobic motif kinase was
attributed to the Rictor-mTOR complex (Sarbassov et al., 2005), also known as mTORC2
(mTOR Complex 2), in both Drosophila and human cells. The mammalian target of
rapamycin (mTOR) serine/threonine kinase is a member of the PI3K-like kinase family
(PIKK) and it is known to be part of two major complexes: mTORC1 and mTORC2.
The mTOR complex 1 (mTORC1) consists of mTOR, the regulatory associated protein of
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mTOR (Raptor) and the mammalian ortholog of yeast LST8 (lethal with SEC13 protein 8).
It can be activated through a pathway involving AKT-mediated phosphorylation of PRAS40
(proline-rich AKT substrate of 40 kD) and the tuberous sclerosis complex, events that
ultimately lead to the activation of the Rheb GTPase (Alessi et al., 2009). mTORC1 activity
is also regulated by the presence of amino acids and the energy balance within the cell.
mTORC1 regulates protein translation through 4EBP1 (eukaryotic translation initiation
factor 4E binding protein 1) and S6K1 (ribosomal S6 kinase 1). In addition to its role in
promoting protein synthesis, S6K1 is also responsible for inhibiting IRS1 activity and IRS2
expression, which provides an important negative feedback for the PI3K pathway (Tremblay
and Marette, 2001).
The second mTOR complex (mTORC2) results from the assembly of mTOR, rapamycininsensitive companion of mTOR (Rictor), mLST8, mammalian stress activated protein
kinase-interacting protein (mSIN1) and protein associated with Rictor (Protor). The activity
of mTORC2 is controlled primarily by PI3K, being largely insensitive to nutrients or energy
conditions (Alessi et al., 2009). In vitro, Rictor is required for mTORC2 to be able to
phosphorylate AKT (Sabatini, 2006). Not much is known regarding the regulation of
mTORC2. However, very recently it has been proposed that during endoplasmic reticulum
(ER) stress, cells respond by downregulating activation of AKT through phosphorylation
and inhibition of Rictor by GSK3β (Chen et al., 2011).
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Figure 2.2. The process of AKT phosphorylation for its activation. Following
activation of receptor tyrosine kinase, phosphorylated tyrosine residues in the RTK’s
cytoplasmic tail become docking sites for the p85 regulatory subunit of PI3K. This
relieves the inhibitory activity of p85 over the catalytic subunit p110 of PI3K, which
in turn phosphorylates the 3’-OH group of PIP2, generating PIP3. PIP3 then
becomes a docking site for molecules containing a PH domain, such as AKT and
PDK1, which come into close proximity at the plasma membrane. PDK1
phosphorylates AKT at Thr308 and this induces a conformational change that allows
for PDK2 (mTORC2 shown here) to phosphorylate AKT on Ser473. Fully active,
now AKT can phosphorylate several of its targets. The phosphatases PP2A and
PHLPPs target the phosphorylated residues on AKT and consequently decrease the
activity of that molecule. PTEN is the phosphatase that targets PIP3, generating PIP2
and counteracting the effects of PI3K.

2.4. Phosphatases targeting AKT
The reversible phosphorylation of AKT is accomplished by the opposing activities of
specific kinases (as previously discussed) and phosphatases (Figure 2.2). Protein
phosphatase 2, also known as PP2A, comprises an actual family of phosphatases with a
highly regulated, well-conserved catalytic subunit. Regulation is accomplished by posttranslational modifications of its catalytic subunit (phosphorylation and methylation) as well
as by interactions with a family of regulatory subunits capable of determining substrate
specificity, subcellular localization and catalytic activity of the holoenzymes (Janssens and
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Goris, 2001). The catalytic subunit of PP2A has been described to undergo phosphorylation
at Tyr307 that is catalyzed by different kinases such as p60v-src, p56lck, as well as by the
activation of epidermal growth factor and insulin receptors. This phosphorylation is
enhanced in the presence of the PP2A phosphatase inhibitor okadaic acid, consistent with an
autodephosphorylation mechanism (Chen et al., 1992). Indeed, more than 90% of the
enzyme’s activity can be lost by this post-translational modification. AKT is one of PP2A’s
substrates. Almost 10 years ago, it was discovered that PP2A not only had the ability to
form a complex with AKT, but also to directly dephosphorylate the active kinase, reducing
its activity by 36% +/- 23% (Ivaska et al., 2002). AKT activity has also been discovered to
be directly repressed by the PH domain leucine-rich repeat phosphatases (PHLPPs)
(Brognard et al., 2007; Gao et al., 2005). Differently from PP2A, these phosphatases target
primarily AKT’s hydrophobic motif, (S473) while PP2A regulates mostly the PDK1 site
Thr308 (Gao et al., 2005). The two PHLPP enzymes seem to have a differential preference
for AKT isoforms: PHLPP1 atennuates the phosphorylation of AKT2 and AKT3 isoforms,
while PHLPP2 dephosphorylates only AKT1 and AKT3 (Brognard et al., 2007). PP1 has
also been assigned participation in the process of AKT inactivation by targeting the
molecule’s Thr450 residue (Xiao et al., 2010). Phosphorylation of Thr450 by JNK has been
described as a potential priming event for the molecule’s full activation (Shao et al., 2006).
Yet, the complete activation of AKT initiates with the recruitment of this molecule to the
plasma membrane by means of interaction of its PH domain with the 3’OH group of PIP3
(Figure 2.2). Since the lipid phosphatase activity of PTEN dephosphorylates the 3phosphoinositide products of PI3K, the activation of PDK1 and also AKT is substantially
regulated by this tumor suppressor. It should be emphasized, however, that PTEN does not
directly dephosphorylate AKT. The stability and consequently activity of PTEN seems to be
controlled by the phosphorylation of multiple residues in its C-terminal domain (mainly
Ser380, Thr382 and Thr383). As constitutively phosphorylated, the molecule remains
mostly in the cytosol. Upon dephosphorylation, plasma membrane recruitment takes place as
well as rapid degradation, which represents a negative feedback of its activity (Das et al.,
2003).
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3. Glycogen Synthase Kinase 3
Discovered as one of the kinases capable of phosphorylating and inactivating glycogen
synthase (Embi et al., 1980), the final enzyme in glycogen biosynthesis, GSK3 was also,
curiously, the first identified substrate of AKT (Cross et al., 1995). In mammalian tissues,
GSK3 exists as 2 isoforms (GSK3α and GSK3β) that share 98% homology of their kinase
domains, while differing substantially in their N-terminal and C-terminal sequences (Force
and Woodgett, 2009). GSK3α has an extended glycine-rich N-terminal tail (Frame and
Cohen, 2001) and therefore a higher molecular weight than the beta isoform (52 kDa versus
47 kDa). The two isoforms may or may not have redundant functions (Beurel and Jope,
2008; Doble et al., 2007; Hoeflich et al., 2000; Wilson and Baldwin, 2008) depending on the
tissue in question and the targets studied. As an example, GSK3α and GSK3β appear to be
redundant in regulating Wnt/β-catenin signaling at the same time that GSK3α primarily
regulates glycogen storage in the liver and GSK3β does it so in the skeletal muscle (Force
and Woodgett, 2009). Interestingly, total absence of GSK3β is embryonically lethal in mice,
due to acute hepatocyte apoptosis (Hoeflich et al., 2000), while GSK3α knockout mice are
viable, displaying enhanced glucose and insulin sensivity accompanied by reduced fat mass
(MacAulay et al., 2007). These differential roles are not a result of differences in expression
of these isoforms. The curious and somewhat recent work from the Newton laboratory raises
the possibility of the isoforms having different affinities when it comes to interacting with
regulators such as the AKT isoforms (Brognard et al., 2007). Other possibilities include
tissue-specific scaffolds that facilitate binding of one versus the other isoform to specific
targets (Force and Woodgett, 2009). Also, two GSK3β species representing alternative
splicing of exon 10 have been idientified (Schaffer et al., 2003). The longer isoform of
GSK3β containing exon 10 seems to be the most prevalent one in all tissues, with the
exception of the brain. The functional consequence of exon 10 splicing is unknown.
The substrate recognition of this kinase is rather unusual. It preferentially targets primed
phosphorylated molecules that contain the following consensus sequence: Ser/Thr-X-X-XSer/Thr-P, where the first Ser or Thr is the target residue, X is any aminoacid (often Pro),
and the phospho Ser/Thr, 4 aminoacids C-terminal to the target residue, is the actual primed
site. Different kinases will prime this site in different molecules. As an example, β-catenin, a
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target of GSK3 in the Wnt signaling pathway, requires priming phosphorylation at Thr45,
prior to being phosphorylated by GSK3 on Thr41, Ser37, and Ser33. In this case, casein
kinase 1 (CK1) seems to be the kinase responsible for the priming (Hagen and Vidal-Puig,
2002). Although priming phosphorylation remarkably increases the efficiency of the GSK3
kinase activity, it is not strictly required.
As a constitutively active serine/threonine kinase, GSK3 for the most part either inactivates
its substrates or flags them for destruction. The E3 ubiquitin ligase β-transducin repeatscontaining protein-1 (β-TrCP1), for example, is able to recognize proteins with two
phosphoserines located four residues apart. Therefore, some of GSK3 targets, such as βcatenin and c-myc, are targeted for ubiquitination and subsequent destruction by the
proteasome (Cohen and Goedert, 2004).

3.1. Regulation of GSK3 activity
GSK3, like other protein kinases such as CDK2, p38γ and ERK2, requires phosphorylation
of residues in its activation loop (T-loop) as a prerequisite for activity (Doble and Woodgett,
2003). The T-loop of GSK3α and GSK3β is phosphorylated at Y279 and Y216,
respectively. However, although this event might substantially facilitate substrate
phosphorylation (>200-fold) (Hughes et al., 1993), it is not absolutely required for kinase
activity.
Since GSK3 is constitutively active in most cell types, negative regulation of its activity
occurs basicaly through one of the following mechanisms: by inactivating its kinase domain,
by altering GSK3 access to its substrates (protein-protein interactions) or by changing its
ability to recognize its substrates (Doble and Woodgett, 2003). The activity of GSK3 kinase
is negatively regulated by phosphorylation of the residues Ser21 and Ser9 in the alpha and
beta isoforms, respectively. This can be accomplished, for example, upon insulin, IGF1 and
EGF stimulation (Cross et al., 1994; Saito et al., 1994; Welsh and Proud, 1993). The
phosphorylated serine residue transforms the molecule’s amino terminus into a
“pseudosubstrate”, with the phosphoserine occupying the same binding site as the priming
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phosphate of the substrate (Cohen and Frame, 2001). This blocks the substrate’s access to
the active kinase site of GSK3. PI3K-induced activation of AKT results in AKT
phosphorylation of both GSK3 isoforms (Cross et al., 1995) (Figure 3.1), but numerous
other kinases can target those serine sites of GSK3, including p90RSK, p70S6K (Sutherland
et al., 1993), PKA (Fang et al., 2000; Li et al., 2000) and PKC (Fang et al., 2002). This
underscores the importance of GSK3 as a convergence node for multiple pathways and
brings light into its potential as a cross-talk mediator.

Figure 3.1. GSK3 activity can be regulated by phosphorylation. In the PI3K
pathway, after AKT becomes phosphorylated and fully active, it phosphorylates
GSK3α/β on Ser21/9, respectively. This post-translational modification can inhibit
the activity of GSK3 towards glycogen synthase. Glycogen synthase, no longer
phosphorylated and inhibited, is free to finalize the multistep process of glycogen
production, a very important end result of the insulin pathway for glucose utilization.

However, inhibition of GSK3 activity is not always achieved through phosphorylation. In
the Wnt signaling pathway, GSK3 plays a central role as the kinase responsible for
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controlling the amount of the transcriptional co-activator β-catenin present within the
cytoplasm, and ultimately dictating the activity of key developmental gene expression
programs. In this pathway, GSK3 regulation does not utilize the same phosphorylation
events as in AKT signaling (Wu and Pan, 2010) (Figure 3.2). In the resting state, the multiprotein β-catenin destruction complex is anchored by AXIN1/2 and adenomatous polyposis
coli (APC). Casein-kinase 1α (CK1α) and GSK3 sequentially phosphorylate β-catenin,
targeting the residues Thr45 (CK1α) and Thr41, Ser37 and Ser33 (GSK3). After being
hyperphosphorylated, β-catenin is recognized by β-Trcp, an E3 ubiquitin ligase subunit, and
then ubiquitinated and proteasomically degrated (Clevers, 2006; MacDonald et al., 2009).
Therefore, in a resting state, levels of free cytosolic β-catenin are kept at a minimum, which
prevents it from reaching the nucleus. Without β-catenin, the DNA-bound T cell
factor/lymphoid enhancer factor (TCF/LEF) family of proteins represses the transcription of
Wnt target genes. Upon Wnt stimulation, interactions between the frizzeled (FZD) receptor
and the cytoplasmic protein disheveld (DVL) and between DVL and Axin, are capable of
localizing the Axin-GSK3 complex to the plasma membrane (Zeng et al., 2008). There,
GSK3 and CK1α sequentially phosphorylate the Wnt co-receptor LRP6 (low density
lipoprotein receptor-related protein 6), a post-translational modification that promotes the
engagement of LRP6 with the scaffolding protein Axin, disrupting the stability of the βcatenin multi-protein destruction complex (Zeng et al., 2005). Hence, GSK3 interestingly
plays both positive and negative regulatory roles in the Wnt signaling pathway. It has also
been demonstrated that GSK3 is subject to another form of regulation in Wnt signaling, also
by means of protein-protein interactions. After Wnt stimulation, a DVL-FRAT (frequently
rearranged in advanced T cell lymphoma) complex may inhibit GSK3 activity towards βcatenin because FRAT can compete with axin for binding to GSK3 (Li et al., 1999).
GSK3 activity is dependent on its subcellular localization, since this protein has been
isolated also in the nucleus and mitochondria. While most of the processes discussed
previously take place in the cytoplasm, the presence of GSK3 in the nucleus grants access to
several of its substrates, including cyclin D1 and c-myc. It has been proposed that GSK3 in
the nucleus may have a role in alternative splicing. In the mitochondria, GSK3 regulates
apoptosis (Ohori et al., 2008). In terms of regulation of the Wnt pathway, a recent study has
implicated the formation of multivesicular bodies (MVBs) as an important regulatory event.
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After Wnt stimulation, Wnt and GSK3 are both sequestered in these endosomal vesicles,
which prevents the access of GSK3 to its target cytosolic protein β-catenin (Taelman et al.,
2010).

Figure 3.2. GSK3 activity is regulated by protein-protein interactions in the
Wnt signaling pathway. In the resting state, the multi-protein β-catenin destruction
complex is anchored by Axin, APC and GSK3. Phosphorylation of APC and Axin by
GSK3 induce conformational changes that keep that complex stable.
Phosphorylation of β-catenin by GSK3 present in that complex, on the other hand,
tags it for ubiquitination and destruction, preventing it from reaching the nucleus.
Following the binding of one of the Wnt molecules to the FZD receptor, interactions
between FZD and DVL are capable of pulling the Axin-GSK3 complex to the
plasma membrane, where GSK3 can phosphorylate the Wnt co-receptor LRP6, a
post-translational modification that promotes further engagement of LRP6 with
Axin. Also, a DVL-FRAT complex formed after Wnt stimulation competes with
Axin for binding to GSK3, again disrupting the structure of the APC-Axin-GSK3
multi-protein β-catenin destruction complex. As a result, β-catenin is no longer
phosphorylated by GSK3 and, as its levels rise considerably, β-catenin translocates
to the nucleus, where it can act as a transcriptional activator of Wnt target genes.
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3.2. GSK3 substrates
GSK3 regulates over 100 putative proteins, including metabolic and signaling molecules, as
well as structural proteins and transcription factors. Since a detailed discussion of how
GSK3 regulates all these possible substrates is outside the scope of this brief introduction,
we will highlight only a few of its targets.
3.2.1. GSK3 and metabolism
Perhaps one of the best known functions of GSK3 is that of being a negative regulator of
glycogen synthesis in the PI3K/insulin signaling pathway. This role was identified back in
1979, when, after being purified from rabbit skeletal muscle, GSK3 was demonstrated to be
able to phosphorylate three serine residues of glycogen synthase (or UDP-glucose-glycogen
glucosyltransferase), reducing its activity (Embi et al., 1980; Rylatt et al., 1980). Also,
inhibition of GSK3 activity results in an approximately twofold increase in glucose uptake
due to a similar increase in protein expression of glucose transporter 1 (GLUT1). This is
reportedly accomplished via phosphorylation and activation of the tumor suppressor and
mTOR inhibitor TSC2 protein, by GSK3 (Buller et al., 2008). Such an extensive and central
role in glucose metabolism has granted GSK3 the status of a highly targetable molecule for
the treatment of Type II Diabetes Mellitus. GSK3 also negatively affects protein synthesis,
by phosphorylating and inhibiting eIF2B (Proud, 2006), as mentioned above.
3.2.2. GSK3 and Wnt signaling
GSK3 participation in the Wnt signaling pathway is of fundamental importance, as
previously described. Although regarded for so long to exhert only a negative regulatory
role in this pathway, by phosphorylating and targeting β-catenin for ubiquitination and
degradation, it also participates in the phosphorylation and activation of the Wnt co-receptor
LRP6. Axin and APC are also substrates of GSK3 in this pathway, as their phosphorylation
enhances the interactions within the β-catenin destructing multi-protein complex, making it
more stable. Through keeping β-catenin levels at check in the cytosol, GSK3 prevents its
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nuclear translocation and the activation of target genes such as c-myc and cyclin D1, which
would ultimately lead to an increase in cell proliferation. Therefore, the idea of therapeutic
GSK3 inhibition is contemplated with great concern due to the possibility of malignancy
development.
3.2.3. GSK3 and Alzheimer’s Disease
The typical histopathological findings in the brains of Alzheimer’s disease patients consist
of multiple deposits of senile plaques composed of amyloid beta-protein, in combination
with neurofibrillary tangles that result from hyperphosphorylated tau proteins (Takashima
et al., 1993). GSK3 has been investigated as one of the most important links between these
two pathological abnormalities. GSK3 not only hyperphosphorylates tau (Kremer et al.,
2011), but also is positively regulated by amyloid beta-protein, which increases GSK3
catalytic activity and induces the appearance of tau proteins (Takashima et al., 1993).
Studies using transgenic mice overexpressing human tau suggest that formation of tau
neurofibrillary tangles might be prevented through inhibition of GSK3 kinase activity
(Noble et al., 2005).
Among the known mechanisms that may contribute to the loss of neurons in Alzheimer’s
brain disease, apoptosis has also received significant attention (Mines et al., 2011). The
intrinsic apoptotic signaling pathway has predominated in studies of Alzheimer’s, and GSK3
mostly promotes this pathway (see discussion below). Therefore, the use of small molecules
targeting GSK3 more and more is seen as a rational and promising strategy for the control of
this neurodegenerative disorder.
3.2.4. GSK3 and apoptosis
GSK3 paradoxically can both promote and inhibit apoptosis. While GSK3 mostly (but not
always) promotes cell death caused by the mitochondrial intrinsic apoptotic pathway, it
inhibits the death receptor-mediated extrinsic apoptotic signaling pathway (Beurel and Jope,
2006). GSK3 promotes the intrinsic apoptotic pathway by several means, including the
direct phosphorylation and resulting increased activity of Bax, a pro-apoptotic Bcl-2 family
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member that elicits cytochrome c release from mitochondria (Linseman et al., 2004). GSK3
also mediates the expression of the pro-apoptotic Bim molecule (Hongisto et al., 2003) and
phosphorylates anti-apoptotic MCL-1, targeting it for ubiquitination and degradation
(Maurer et al., 2006). The induction of apoptosis is central to the tumor-suppressive activity
of p53, which can promote the expression of a number of genes that are involved in
apoptosis, including proapoptotic members of the Bcl-2 family. And GSK3β (but not
GSK3α) has been demonstrated to phosphorylate and positively regulate the activity of
phospho Ser33-p53 (Turenne and Price, 2001). However, during ER stress, GSK3β
phosphorylates p53 on different residues (Ser315 ad Ser376), inducing its cytoplasmic
localization and preventing its stabilization (Turenne and Price, 2001). The Mdm2
oncoprotein, which regulates abundance and activity of p53, can also be phosphorylated by
GSK3. As Mdm2 becomes more stable with this post-translational modification, degradation
of p53 is consequently enhanced (Kulikov et al., 2005).
The negative regulatory role of the extrinsic apoptotic pathway by GSK3 became clear when
knockout GSK3β mice studies showed embryonic lethality due to massive hepatic
degeneration (Hoeflich et al., 2000), a phenotype that was consistent with extensive TNFinduced hepatocyte cell death. Those investigators also were able to link the pro-apoptotic
effects of GSK3β’s absence to an impaired transcriptional activity of NF-kappaB. Later
studies have discovered the formation of a GSK3 complex with two other proteins called
DEAD-box polypeptide 3 (DDX3) and cellular inhibitor of apoptosis protein-1 (cIAP-1) that
caps all death receptors in different cell lines (Sun et al., 2008). This restrains the formation
of the death-inducing signaling complex (DISC) and subsequent caspase-8 activation. In
cancer cells that are resistant to death receptor stimulation, this anti-apoptotic complex is
functional, and resistance can be overcome by the use of GSK3 inhibitors.
In conclusion, GSK3 is a complex regulator of apoptosis, displaying a myriad of effects that
could both promote and protect from cell death. Further studies are needed to establish the
major factors that would predict the final outcome if inhibition of GSK3 activity is
undertaken in a variety of settings where apoptosis is a harmful event to be prevented or a
desired outcome to be pursued.
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3.2.5. GSK3 in Hedgehog signaling
The Hedgehog signaling pathway, first identified in Drosophila and one of the key
regulators of animal embryo development, now is recognized as aberrantly activated in a
variety of cancers, including basal cell carcinoma, medulloblastomas and pancreatic cancers
(Katoh and Katoh, 2009). In this pathway, unstimulated cells have the cytosolic Cubitus
interruptus (Ci) in Drosophila and Gli in mammalians targeted for proteolysis. The result of
such cleavage is the production of a truncated transcriptional repressor that undergoes
nuclear translocation and prevents the transcription of Hh target genes. The binding of Hh
ligand to patched receptors leads in turn to a rise in the levels of uncleaved Ci, which acts as
a transcriptional activator. In Drosophila, GSK3 antagonizes Hedgehog signalling by
phosphorylating Ci (after a primed phosphorylation by PKA) and facilitating its proteolytic
cleavage (Jia et al., 2002).
3.2.6. GSK3 and the JNK pathway
The c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) pathway is one of
the three recognized MAPK pathways (the other ones being the ERK and the p38 MAPK
pathways). Though a variety of stimuli leads to JNK activation (UV light exposure, heat
shock and other stress related conditions) growth factors, especially ligands for GPCRs (Gprotein coupled receptors) usually induce only a modest increase in JNK activity, while
ERK tends to be markedly active after GPCR stimulation. It has been demonstrated that
GSK3 is responsible for inhibiting the activation of JNK following GPCR and EGFR
stimulation, while mediating UV light-mediated JNK activation (Liu et al., 2004).
JNK activated proteins include some of the AP-1 transcription factors. The activating
protein-1 (AP-1) homodimers and heterodimers consist of basic region-leucine zipper DNA
binding proteins involved in the control of cell proliferation, survival and death (Shaulian
and Karin, 2001). Those proteins belong mostly to the Jun (c-Jun, JunB and JunD), Fos and
activating transcription factors (ATF) subfamilies. AP-1 proteins, after a variety of stimuli
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(such as growth factors, inflammatory cytokines and UV radiation), are set to regulate the
expression and function of cell cycle regulators. c-Jun is unique in its ability to stimulate cell
proliferation by repressing tumor suppressor expression and inducing cyclin D1
transcription (Shaulian and Karin, 2001). The activity of c-Jun is controlled both at the
transcription level and at the post-translational level. Different phosphorylation sites regulate
its capability to bind to DNA (Morton et al., 2003) and stability. Phosphorylation of the cJun C terminal domain by GSK3 leads to the polyubiquitination and degradation of c-Jun
(Wei et al., 2005).

3.3. GSK3 mediates signaling upstream of AKT
Work carried out in our lab (Lu et al., 2011) to identify regulators of intracellular signaling
has utilized an siRNA screen targeting a total of 541 kinases and kinase-related molecules.
Changes in signaling determined through a reverse phase protein array (RPPA) screen
looking at 42 phospho and total proteins revealed that genetic ablation of GSK3 significantly
blocks AKT phosphorylation, an unexpected observation (Lu et al., 2011).
Further work (Smith, 2010) exploring those findings led to confirmation that in three
different cell lines GSK3 presence was necessary for AKT activation and phosphorylation.
In GSK3 β-/β- mouse embryonic fibroblasts, siRNA targeting the GSK3 α isoform abrogated
AKT phosphorylation (Figure 3.3). Also, in the breast cancer cell lines MDA-MB-231 and
AU565, targeting both GSK3 isoforms affected negatively AKT phosphorylation and
activation (Smith, 2010). It remained unclear if that effect on AKT phosphorylation was
dependent on the kinase activity of GSK3. This effect was probably a cell-context dependent
signaling mechanism, since other cell lines also screened with siRNA (MDA-MB-415,
T47D and MCF7) did not demonstrate dependency on GSK3 presence for AKT
phosphorylation.
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Figure 3.3. GSK3 mediates EGF signaling to AKT in Mouse Embryonic
Fibroblasts (MEFs). GSK3β knockout MEFs were transfected with GSK3α siRNA
or control nontargeting siRNA. 48 hours after transfection cells were serum-starved
overnight and then stimulated with EGF (60 ng/ml). Cell lysates were analyzed for
AKT, AKT phospohorylation (Thr308 and Ser473), and GSK3α. GAPDH was used
as a loading control (Smith, 2010).
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MATERIALS AND METHODS
4.1. Cells
Tumor cell lines MDA-MB-231, MDA-MB-468, SKBR3, HCC1569, HCC1964, BT474 and
WM35 were obtained from the ATCC and cultured in RPMI 1640 medium supplemented
with 5% fetal bovine serum (FBS). All cells were maintained at 370C with 5% CO2.
4.2. Antibodies
Rabbit polyclonal antibodies against AKT, phospho-AKT (Thr308), phospho-AKT
(Ser473), β-catenin, phospho-β-catenin (Ser33/37/Thr41), β-actin, glycogen synthase,
phospho-glycogen synthase (Ser641), mTOR, Rictor, PDK1, phospho PDK1 (Ser241),
phospho-Hsp27 (Ser82), PP2A catalytic subunit, phospho PP1A (Thr320), PTEN, phospho
EGFR (Tyr1068), p38 MAPK, phospho p38 MAPK (Thr180/Tyr182), and phospho-Hsp 27
(Ser82) were purchased from Cell Signaling Technology (Beverly, MA). The rabbit
monoclonal antibodies against phospho PTEN (Ser380/Thr382/383) (Clone 44A7), IGF-1
Receptor β (Clone 111A9) and phospho-IGF-1 Receptor β (Tyr1135/1136)/Insulin Receptor
β (Tyr1150/1151) (Clone 19H7) were also obtained from Cell Signaling Technology
(Beverly, MA). The monoclonal mouse antibody against GSK3 α/β (Clone 0011-A) and the
rabbit polyclonal antibody against EGFR were obtained from Santa Cruz Biotechnology, Inc
(Santa Cruz, CA). The mouse monoclonal antibody against PRAS40 (Clone 73P21) and the
rabbit polyclonal antibody against phospho PRAS40 (Thr246) were obtained from
Invitrogen (San Diego, CA). The rabbit monoclonal antibody against PP1A (EP1511Y) was
obtained from Novus Biologicals (Littleton, CO). The rabbit monoclonal antibody against
phospho PP2A (Tyr307) (Clone E155) was obtained from Epitomics (San Francisco, CA).
The mouse monoclonal antibody against GAPDH (Clone 6C5) was purchased from Ambion
(Austin, TX). Antibodies against PHLLP1 and PHLLP2 were generously provided from Dr.
Alexandra C. Newton’s lab. The antibodies used in the reverse phase protein array
experiment have been previously described (Hong et al., 2010).
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4.3. Growth factors and small molecule inhibitors
Epidermal growth factor (EGF) was purchased from R&D Systems (Minneapolis, MN) and
the insulin growth factor 1 (IGF-1) was purchased from Millipore (Billerica, MA). When
cells were stimulated with growth factors, serum-starvation overnight was performed,
followed by a 20-minute stimulation, and then lysis of the cells. The concentrations of the
growth factors utilized were 60 ng/ml and 50 ng/ml for EGF and IGF-1, respectively. In the
reverse phase protein array experiments, the concentrations were 60 ng/ml and 100 ng/ml,
for EGF and IGF-1 respectively.

The GSK3 inhibitors SB 216763, SB 415286 and CT

99021 were purchased from Sigma (St. Louis, MO). The p38 inhibitor SB 202190 was
purchased from Tocris Bioscience (Bristol, UK). All small molecule inhibitors were
dissolved in dimethyl sulfoxide.
4.4. siRNAs and Transient Transfections
siRNAs targeting human GSK3α (pooled siRNA L-003009-00), human GSK3β (pooled
siRNA L-003010-00), and nontargeting RISC-Free control siRNA were purchased from
Dharmacon (Lafayette, CO). Pan-GSK3 siRNA was purchased from Ambion (Austin, TX).
Cells were subjected to transient transfections using LipofectamineTM RNAiMAX
Transfection Reagent purchased from Invitrogen (San Diego, CA) according to the
manufacturer’s instructions. Most cell lines were able to be efficiently transfected by the
forward method, where cells were plated 24 hours prior to transfection at approximately
50% confluence. For the forward transfections, serum-free medium was substituted for
regular medium 20 minutes prior to transfection, when siRNAs or RISC-Free control was
added to the cells, together with the transfection reagent. Regular medium was then
substituted for serum-free medium 6 to 8 hours after transfection. The cell lines T47D and
SKBR3 were subjected to reverse transfection, where cells and transfection reagent in
combination with siRNAs or RISC-Free control were mixed at the same time cells in
suspension were re-platted at approximately 60% confluence. Cells in the reverse
transfection were plated in regular, serum-containing medium. The culture medium was
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changed after the cells attached to the surface, approximately 24 hours following
transfection. In the experiments using transient transfection, cells were typically harvested
72 hours after transfection was performed.

4.5. Western Blotting
Cells were washed by ice-cold phosphate buffered saline (PBS), scraped from the cell
culture dish, collected, pelleted and resuspended in lysis buffer pH 7.5 (1% Triton X 100,
10% glycerol, 10 mM EDTA, 10 mM NaCl, 50 mM HEPES), with the addition of the
protease inhibitor mixture from Roche Applied Science (Branford, CT), 10µg/mL aprotinin,
1 mM sodium vanadate and 1 mM phenylmethylsulfonyl fluoride. Lysates were centrifuged
at maximum speed for 15 minutes and the clarified supernatant containing the protein was
collected. Protein concentrations were measured by protein assay from Bio-Rad (Hercules,
CA) according to the manufacturer’s instructions. Samples containing 25-30 µg of total
protein were prepared with lamelli buffer and resolved by SDS-PAGE, transferred to
polyvinylidene difluoride membranes, and immunoblotted with antibodies following the
protocols provided by the manufacturer’s.
4.6. Reverse Phase Protein Array (RPPA)
Cellular proteins were denatured by 1% SDS (with β-mercaptoethanol) and diluted in five 2fold serial dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial diluted
lysates were arrayed on nitrocellulose-coated slides (Grace Biolab, Bend, OR) using an
Aushon 2470 Arrayer (Aushon BioSystems, Inc, Billerica, MA). Each slide was probed with
a different validated primary antibody plus a biotin-conjugated secondary antibody using a
BioGenex Autostainer and a Dako amplification kit. Slides were then scanned to provide
images for densitometry measurement by MicroVigene microarray image analysis software.
Relative signal intensities for each antibody were then quantitated using a “SuperCurve”
method (http://bioinformatics.mdanderson.org/OOMPA) which fits all data onto a common
curve and maps each sample data point onto the curve. Positive and negative controls were
present in each slide to ensure quality of slide printing and its analysis. Antibodies used for
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RPPA have been validated through correlation of western blot results with RPPA analysis
and measurement of the RPPA signal dynamic range.
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RESULTS
5.1. GSK3 alpha and beta isoforms play a redundant role in AKT phosphorylation
In the breast cancer cell line MDA-MB-231, the use of siRNA targeting both isoforms of
GSK3 caused a remarkable decrease in the phosphorylation of AKT on both sites required
for its full activity (Thr308 and Ser473), while pooled siRNA targeting each isoform of
GSK3 separately did not (Figure 5.1). AKT phosphorylates proline-rich AKT substrate of
40 kDa (PRAS40) on Thr246 (Kovacina et al., 2003). Levels of phosphoThr246 PRAS40 as
measured by western blot correlated with the decrease in AKT phosphorylation indicating
that the decreased phosphorylation lead to decrease in AKT activity. Both EGF and IGF
were utilized as inducers of PI3K pathway activation in this model and the effect on AKT
activation caused by the decrease in GSK3 dosage is seen irrespective of the receptor
tyrosine kinase activated. This result underscores the generalizability of the observed effect
and discards a feedback loop involving IRS-1 as major cause of attenuation of AKT
activation as IRS-1 is not required for EGFR signaling.
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Figure 5.1. GSK3 isoforms alpha and beta have a redundant role in AKT
phosphorylation in the MDA-MB-231 cell line. MDA-MB-231 cells were treated
with transfection reagent alone (mock) or transiently transfected with non-targeting
siRNA (scramble), siRNA targeting GSK3α, GSK3β or both GSK3 isoforms. Cells
were lysed 72 hours after transfection. Cells were serum-starved the evening before
lysis and then stimulated with IGF 50 ng/ml (+) or EGF (+) 60 ng/ml for 20 minutes
followed by lysis and immunoblotting. The symbol (-) denotes no growth factor
stimulation.
Targeting both isoforms of GSK3 in the Her-2 amplified breast cancer cell line SKBR3,
where AKT is activated due to HER2 amplification independent of exogenous ligand, also
led to decreased AKT phosphorylation and activity (Figure 5.2).
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Figure 5.2. Knock-down of GSK3 isoforms alpha and beta in the HER-2
overexpressing breast cancer cell line SKBR3 impairs AKT activation. SKBR3
cells were transiently transfected with non-targeting siRNA (scramble) or siRNA
targeting both isoforms of GSK3. Cells were lysed 72 hours after the transfection.
The cells that were serum-starved the evening before lysis were stimulated with IGF
50 ng/ml (+) for 20 minutes followed by lysis and immunoblotting. The symbol (-)
denotes no growth factor stimulation.

A much weaker dependency on GSK3 for the phosphorylation of AKT was observed in the
melanoma cell line WM35 (Figure 5.3A) and complete independence was seen in the breast
cancer cell line T47D (Figure 5.3B). Thus GSK function is required for optimal AKT
phosphorylation in many but not all lines and across multiple mechanisms of cellular
activation.
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Figure 5.3. The effect of GSK3 inhibition on optimal AKT phosphorylation is
cell-specific. (A) WM 35 melanoma cells were transiently transfected with nontargeting siRNA (scramble) or siRNA targeting GSK3α/β. Cells were lysed 72 hours
after the transfection. Cells were serum-starved the evening before lysis and were
stimulated with IGF 50 ng/ml (+) for 20 minutes followed by lysis and
immunoblotting. The symbol (-) denotes no growth factor stimulation. (B) T47D
cells were transiently transfected with non-targeting siRNA (scramble) or siRNA
targeting GSK3α/β. Cells were lysed 72 hours after the transfection. Cells were
serum-starved the evening before and were stimulated with IGF 50 ng/ml (+) for 20
minutes followed by lysis and immunoblotting. The symbol (-) denotes no growth
factor stimulation.

5.2 The kinase activity of GSK3α/β is required for the optimal phosphorylation of
AKT
GSK3 is known to be embedded in multi-protein complexes and protein-protein interactions
as well as subcellular localization are essential to some of its regulatory functions.
Therefore, we asked if the observed effects on AKT phosphorylation could also be
demonstrated by the use of small molecules targeting only the kinase activity of GSK3. CT
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99021 is an ATP-mimetic that is both a highly potent and specific inhibitor of both GSK3
isoforms (Bain et al., 2007). In MDA-MB-231 cells, treatment with CT 99021 led to a
remarkable decrease in AKT phosphorylation, compared to vehicle alone (Figure 5.4).
Ser33/37 and Thr41 of β-catenin that are targets for phosphorylation by GSK3 were
measured as a marker of GSK3 kinase activity. As expected, total β-catenin levels increased
modestly in the presence of GSK3 inhibition. Similar results were observed in two other
breast cancer cell lines, HCC 1954 and HCC 1569 (Figure 5.5).

Figure 5.4. The kinase activity of GSK3α/β is required for the optimal
phosphorylation of AKT in the MDA-MB-231 cell line. MDA-MB-231 cells were
treated with the GSK3 kinase inhibitor CT 99021 (5µM) for 24 hours or DMSO at
0.025% as a control. Cells were stimulated (+) or not (-) with IGF (50 ng/ml) for 20
minutes following serum-starvation overnight and lysed for immunoblotting.
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Figure 5.5. The kinase activity of GSK3α/β is required for the optimal
phosphorylation of AKT in two other cell lines. (A) HCC1954 cells were treated
with the GSK3 kinase inhibitor CT 99021 (2.5µM and 5µM) for 24 hours or DMSO
at 0.025% as a control. Cells were stimulated (+) or not (-) with IGF (50 ng/ml) for
20 minutes following serum-starvation overnight and lysed for immunoblotting. (B)
HCC1569 cells were treated with the GSK3 kinase inhibitor CT 99021 (2.5µM and
5µM) for 12 and 24 hours or DMSO at 0.025% as a control. Cells were stimulated
(+) or not (-) with IGF (50 ng/ml) for 20 minutes following serum-starvation
overnight and lysed.
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The effects observed above were not restricted to the drug CT 99021. Two other GSK3
inhibitors, SB 216763 and SB 415286, were tested to see if they could also affect AKT
phosphorylation. Compared to vehicle, the use of two different concentrations of those
inhibitors led to a decrease in AKT phosphorylation (Figure 5.6).

Figure 5.6. Inhibition of GSK3 kinase activity with different ATP mimetics
leads to a decrease in AKT phosphorylation. MDA-MB-231 cells were treated
with the GSK3 kinase inhibitors SB 216763 at two different concentrations (5µM
and 10µM), SB 415286 at two different concentrations (10µM and 20µM) or DMSO
as a control, for 24 hours. All cells were stimulated with IGF (50 ng/ml) for 20
minutes following serum-starvation overnight and lysed for immunoblotting.

In BT 464 breast cancer cells, however, despite a remarkable inhibition of GSK3 activity (as
measured by reduced levels of phosphorylated Ser641 in Glycogen Synthase), almost no
effect on AKT phosphorylation was seen (Figure 5.7), underscoring the cell-specificity of
the dependency of GSK3 kinase activity for full AKT phosphorylation and activation.
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Figure 5.7. The effect of GSK3 kinase inhibitors on AKT phosphorylation is
cell-specific. BT474 cells were treated with the GSK3 kinase inhibitor CT 99021
(2.5µM and 5µM) for 12 and 24 hours or DMSO at 0.025% as a control. Cells were
stimulated (+) or not (-) with IGF (50 ng/ml) for 20 minutes following serumstarvation overnight and lysed for immunoblotting.

5.3. Inhibition of GSK3 does not lead to changes in levels of putative kinases
involved in AKT phosphorylation
In the canonical PI3K pathway, AKT activation occurs following the phosphorylation of
Thr308 and Ser473 residues by PDK1 (Alessi et al., 1997b) and PDK2 respectively. In most
conditions and cell types, PDK2 is mTORC2 (Sarbassov et al., 2005). We hypothesized that
inhibition of GSK3 could have led to a decrease in the levels of these kinases, which would
in turn impact the phosphorylation of AKT. In MDA-MB-231 cells that had been treated
with siRNA targeting GSK3α/β and exhibiting a remarkable decrease in AKT
phosphorylation and activity, we measured by immunoblotting the total levels of PDK1, as
well as phosphorylated Ser241 on its activation loop (necessary for its activity)(Casamayor
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et al., 1999), mTOR and RICTOR (Figure 5.8). No differences were detected between
control and treatment groups.

Figure 5.8. GSK3 inhibition does not affect levels of known kinases involved in
AKT signaling. MDA-MB-231 cells were transiently transfected with non-targeting
siRNA (scramble) or siRNA targeting both isoforms of GSK3. Cells were lysed 72
hours after the transfection. Cells were serum-starved the evening before the
treatment and were stimulated with IGF 50 ng/ml (+) for 20 minutes followed by
lysis and immunoblotting.
5.4. Inhibition of GSK3 does not lead to changes in levels of putative phosphatases
involved in AKT dephosphorylation
The phosphorylated state of AKT requires an equilibrium between the activities of kinases
and phosphatases that target phosphosites. As presented above, Thr308 in AKT is a target of
protein phosphatase 2A or PP2A (Ivaska et al., 2002) while the PH domain leucine-rich
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repeat phosphatases (PHLPP) 1 and 2 have selectivity for the hydrophobic phosphorylation
motif of AKT, Ser473 (Brognard et al., 2007; Gao et al., 2005). Also, PP1A has been
demonstrated to regulate AKT1 signal transduction by dephosphorylating the AKT residue
Thr450, which seems to be an important phosphorylated residue required to prime AKT for
activation (Xiao et al., 2010). Phosphorylation of Tyr307 of PP2A and of Thr320 of PP1A
results in inactivation of these enzymes (Janssens and Goris, 2001; Kwon et al., 1997).
We hypothesized that an increase in the total levels or modifications that increase the
activity of these important phosphatases could be causes for a decrease in AKT
phosphorylation. There was, however, no difference in those levels as measured by
immunoblotting following treatment of MDA-MB-231 cells with siRNA targeting GSK3α/β
(Figure 5.9).
The phosphatase and tensin homologue PTEN is a tumor suppressor that reverses the action
of PI3K by catalyzing the removal of the 3’ phosphate of phosphoinositides, which results in
a diminished amount of AKT being mobilized to the plasma membrane for phosphorylation
and activation. Several studies have indicated that PTEN is constitutively phosphorylated on
Ser370, Ser380, Thr382, Thr383 and Ser385 in the C-terminal tail and dephosphorylation of
these residues leads to increased membrane localization and decreased stability (Das et al.,
2003). No increase in total levels of PTEN or decrease in its most stable, phosphorylated
form was observed in MDA-MB-231 cells treated with siRNA targeting GSK3α/β (Figure
5.9).

40

Figure 5.9. GSK3 inhibition does not affect levels of known phosphatases
involved in AKT signaling. MDA-MB-231 cells were transiently transfected with
non-targeting siRNA (scramble) or siRNA targeting both isoforms of GSK3. Cells
were lysed 72 hours after the transfection. Cells were serum-starved the evening
before the treatment and were stimulated with IGF 50 ng/ml (+) for 20 minutes
followed by lysis and immunoblotting.

5.5. Inhibition of GSK3 does not lead to changes in levels of receptor tyrosine
kinases
Ultimately, PI3K activation initiates with the activation and phosphorylation of the receptor
tyrosine kinases (RTKs) implicated in each signaling event. A decrease in total or
activated/phosphorylated levels of IGF1R and EGFR upon IGF and EGF stimulation,
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respectively, could potentially lead to a decrease in PI3K activation and AKT
phosphorylation. However, no differences in receptor levels were detected between
treatment groups and controls (Figure 5.10). Thus changes in the various kinases,
phosphatases and RTKs known to regulate AKT activity are not sufficient to explain the
mechanism by which GSK3 regulates AKT phosphorylation.

.

Figure 5.10. GSK3 inhibition does not affect levels of growth factor receptors.
MDA-MB-231 cells were transiently transfected with non-targeting siRNA
(scramble) or siRNA targeting both isoforms of GSK3. Cells were lysed 72 hours
after the transfection. The cells that were serum-starved the evening before the
treatment were stimulated with IGF 50 ng/ml or EGF 60 ng/ml (+) for 20 minutes
followed by lysis and immunoblotting.
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5.6. Reverse Phase Protein Array identifies an increase of MAPK phospho-p38
(Thr180) as a result of GSK3 inhibition
After performing a candidate molecule based interrogation on levels of the proteins expected
to be involved in the process of AKT phosphorylation, we decided to perform a broader and
more comprehensive analysis of the proteomic changes associated with the inhibition of
GSK3. Reverse-phase protein arrays (RPPA) use micro-scale, cell lysate dot blots that are
printed to a substrate, followed by quantitative immunochemical protein detection (Spurrier
et al., 2008). Because it can generate 1,000 times more data points using 10,000 times less
sample volume than an ordinary western blot, RPPA provides a high-throughput and
objective analysis of multiple proteins in very small amounts of sample. Following 72 hours
of transfection of MDA-MB-231 cells with either GSK3α, GSK3β, pan-GSK3 siRNA or
control non-targeting siRNA, cells were stimulated with IGF or no growth factor and lysed.
Cell lysates were then processed on a reverse phase protein array and stained for 88
antibodies targeting different proteins and phosphoproteins. Two different siRNA
experiments were conducted for this analysis. The average expression of the measured
proteins was plotted in bar graphs for further visualization and comparison. An expected fall
in the levels of GSK3 and phosphorylated AKT at Ser473 and Thr308 residues provided an
important validation for the experiments (Figures 5.11A, 5.11B and 5.11C). We then
looked for proteomic changes of at least 50% in the treatment groups compared to controls
and detected an unexpected increase in the phosphorylated form of the MAPK p38 (Figure
5.11D), indicating the potential activation of this pathway following GSK3 inhibition in this
cell line. Western blot analysis of samples from a different experiment in MDA-MB-231
cells confirmed the unexpected increase in phosphorylated p38 levels (pThr180/Tyr182)
(Figure 5.11E).
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Figure 5.11. Reverse Phase Protein Array identifies an increase of MAPK phospho-p38
(T180) as a result of GSK3 inhibition. MDA-MB-231 cells were transfected with siRNA
targeting either GSK3 alpha (siα), beta (siβ), or both isoforms of GSK3 (siα/β) or control nontargeting siRNA (Scr). Seventy-two hours later, cells were stimulated (+) for 20 minutes with
IGF (100 ng/ml) or no growth factor (-), following overnight serum-starvation. Cell lysates were
processed on a reverse phase protein array and stained for antibodies targeting 88 different
proteins and phosphoproteins. The bars represent the average of expression levels obtained in
two experiments. (A) Average of GSK3 total levels by RPPA analysis in two different
experiments. (B) Average of phospho-AKT S473 levels by RPPA analysis in two different
experiments. (C) Average of phospho-AKT T308 levels by RPPA analysis in two different
experiments. (D) Average of phospho-p38 T180 levels by RPPA analysis in two different
experiments. (E) MDA-MB-231 cells were transfected with non-targeting siRNA (scramble) or
siRNA targeting both isoforms of GSK3. Cells were lysed 72 hours after the transfection. Cells
were serum-starved the evening before and stimulated with IGF 50 ng/ml (+) for 20 minutes
followed by lysis and immunoblotting. The symbol (-) denotes no growth factor stimulation.
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5.7. Inhibition of p38 activity restores optimal AKT phosphorylation despite GSK3
inhibition
The p38 mitogen-activated protein kinase (MAPK) pathway is strongly activated by stress,
but also plays important roles in the immune response and regulation of cell survival and
differentiation (Cuadrado and Nebreda, 2010). MAPK kinase 3 (MKK3), MKK6 and
sometimes MKK4 activate p38 MAPK by phosphorylation at Thr180 and Tyr182
(Raingeaud et al., 1995). The two major groups of proteins that are regulated by p38
MAPK-mediated phosphorylation are transcription factors and protein kinases, such as
MAPK-activated protein kinase-2 (MAPKAPK-2) (Rouse et al., 1994). MAPKAPK-2
phosphorylates a myriad of targets, including the heat-shock protein of 27 kDa (Hsp27)
(Ahlers et al., 1994). The finding of an unexpected increase in phosphorylated p38 levels in
MDA-MB-231 cells treated with siRNA targeting GSK3 led us to hypothesize that p38
could be critical for the effect of GSK3 inhibition on AKT phosphorylation and activation in
that cell line. To test that hypothesis we used a p38 kinase inhibitor, SB202190, in MDAMB-231 cells that had been previously treated with siRNA targeting GSK3α/β. We
observed that treatment of those cells with SB202190 completely restored AKT
phosphorylation in response to IGF in the presence of GSK3 knockdown (Figure 5.12), as
measured by immunoblotting. Thus, GSK3, through modulating p38 activity, is required for
optimal AKT phosphorylation in MDA-MB-231 cells.
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Figure 5.12. Inhibition of p38 activity restores optimal AKT phosphorylation
despite GSK3 inhibition. MDA-MB-231 cells were transfected with non-targeting
siRNA (scramble) or siRNA targeting both isoforms of GSK3. Forty-eight hours
later, cells were treated with 10 µM of the p38 inhibitor SB202190 for 3 hours or
vehicle (DMSO). Cells were serum-starved the evening before and were stimulated
with IGF 50 ng/ml (+) for 20 minutes followed by lysis and immunoblotting. The
symbol (-) denotes no growth factor stimulation.
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DISCUSSION
As previously discussed, GSK3 plays a remarkable role in a number of metabolic and cell
fate determining events, therefore constituting a desirable target for the treatment of a
variety of disorders, some of them increasingly prevalent in the past years, such as Type II
Diabetes Mellitus and Alzheimer’s dementia. It is thought, for example, that a significant
proportion of the therapeutic effects of lithium as a mood stabilizer stems from the
capability of this drug to inhibit GSK3, even though this inhibition is far from selective.
Accordingly, a number of novel, potent and fairly selective small-molecule GSK3 inhibitors
have been developed (Medina and Castro, 2008). The majority of them constitute ATPcompetitive inhibitors, and some new compounds exhibit substrate-competitive inhibition
activity. None of these inhibitors has demonstrated isoform selectivity so far. SB 216763
and SB 415286 are two potent and selective maleimide compounds that, by ATPcompetitive action, inhibit GSK3 with K(i)s of 9 nM and 31 nM, respectively (Coghlan et
al., 2000). In the presence of 0.1 mM ATP, 10 µM SB 216763 and SB 415286 inhibit
GSK3 kinase activity by 96% and 83%, respectively (Coghlan et al., 2000). CT 99021 is
even a more potent and specific inhibitor of GSK3, capable of not inhibiting any other
kinase at 1 µM, except for CDK2-cyclin A (IC50 – 1.4 µM) (Bain et al., 2007). Therefore, it
has been recommended using CT 99021 to inhibit GSK3 in cells, as it is the most potent and
specific inhibitor available (Bain et al., 2007). Currently, tideglusib (NP 031112), a nonATP competitive GSK3 inhibitor of the thiadiazolidindione family, has been granted fast
track status by the Food and Drug Administration for the treatment of the neurodegenerative
disorder progressive supranuclear palsy. This compound is also undergoing Phase II trials in
Alzheimer’s disease patients.
However, one of the major concerns regarding the use of GSK3 inhibitors stems from the
knowledge that this molecule exerts pivot antagonistic effects to major pathways involved in
cell proliferation, such as Wnt, PI3K and JNK/c-Jun. What if prolonged GSK3 inhibition
leads to the activation of mediators of cell proliferation and tumor promotion? In this study,
we document the unexpected dependency of AKT, the major effector node in the PI3K
pathway, on GSK3. It is only when GSK3 is present that AKT becomes phosphorylated at
Thr308 and Ser473 residues, with an observed increased phosphorylation of typical targets.
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This is an important shift from the current paradigm of GSK3 as a tumor suppressor.
Through the use of both siRNA technique and small, very potent and specific GSK3
inhibitors, we have been able to demonstrate that GSK3 activity is needed for AKT to
become fully active in a variety of cell lines, including human breast cancer and human
melanoma. Previous work in our lab has confirmed the need of GSK3 for the full activation
of AKT in murine embryonic fibroblasts, a non-malignant cell line.
Although GSK3 isoforms do not always demonstrate overlapping functional roles, in our
studies

either

GSK3α

or

GSK3β

presence

is

sufficient

to

promote

AKT

activation/phosphorylation. It is only when siRNA targeting both GSK3 isoforms is
effectively utilized that AKT phosphorylation and activation is impaired. Since these
isoforms share 98% homology within their kinase domains, but differ substantially in their
N- and C-terminal sequences (Force and Woodgett, 2009), we raised the question whether
the effect on AKT phosphorylation was dependent primarily on the kinase activity of GSK3.
GSK3 is well known for regulating other molecules by means of protein-protein
interactions, and this is mostly exemplified in the Wnt signaling pathway. Using three
different ATP-competitive inhibitors of GSK3, we have recapitulated the effect we had seen
initially with RNA interference, establishing that the kinase activity of GSK3 is needed for
full AKT activation and phosphorylation. Ideally, we would like to confirm this finding in
GSK3 kinase inactive mutants, and this idea should be tested in future experiments.
The ability of GSK3 to phosphorylate insulin receptor substrate-1 (IRS-1) has been
described as a potential inhibitory mechanism for insulin resistance in Type 2 Diabetes
(Eldar-Finkelman and Krebs, 1997; Liberman and Eldar-Finkelman, 2005). As IRS-1 is an
important docking molecule for IGF-1R (Baserga, 1999), we raised the question whether the
observed effect of GSK3 inhibition on AKT activation was not another representation of a
feedback loop involving IRS-1. However, we were able to detect similar effects when EGF
was used as a stimulus for the PI3K pathway activation and in cells where the PI3K pathway
is activated by overexpression of HER2 indicating that the effect of GSK3 on AKT
phosphorylation cannot be explained solely by feedback inhibition of IRS-1. Dependency on
GSK3 is also demonstrated in the non-stimulated states of cells that already bear a high
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baseline level of AKT activity and phosphorylation (HER2 overexpressing cell lines SKBR3
in Figure 5.2 and HCC 1954/HCC 1569, in Figure 5.5).
Cell lines with different genetic mutations have been interrogated for this effect of GSK3 on
AKT phosphorylation (Table 1). At this point, we have not been able to establish a
commonality in the signaling processes that drive proliferation and survival in these cell
lines and that could explain the mechanism of this observed effect. Having said that, one
possible pattern can be described here. The one that mostly stands out is the fact that all
HER2 overexpressing cell lines tested displayed either dramatic or some effect on AKT
phosphorylation after GSK3 inhibition. HER2, one of the 4 members of the EGFR/ErbB
RTK family, upon homodimerization or heterodimerization (Wang et al., 2011) with other
members of the EGFR family, commands the activation of PI3K and MAPK pathways
(Karunagaran et al., 1996; Waterman et al., 1999), leading to increased proliferative and
migration capabilities. PI3K pathway activation in breast cancers, defined as PTEN loss
and/or PIK3CA mutations, has been associated with resistance to trastuzumab and lapatinib
and also shorter survival times (Wang et al., 2011). Trastuzumab resistance has also been
associated with signaling ignited by IGF1R (Nahta and Esteva, 2006). Therefore, it is at
least very encouraging to find that GSK3 inhibition in the setting of HER2 overexpression
negatively impacts the activation of AKT, the major effector node of the PI3K pathway. A
greater number of HER2 overexpressing cell lines needs to be screened and the interaction
of GSK3 inhibitors with HER2 targeting therapy should be investigated.
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Table 1. Cell lines screened for the effect of GSK3 inhibition on AKT
phosphorylation. Depicted in green are the cell lines where GSK3
presence/activity is clearly necessary for full AKT phosphorylation and activation.
In yellow, the cell lines where GSK3 inhibition decreases some of AKT
activation/phosphorylation, but not dramatically. In red, cell lines where no effect
was observed in AKT phosphorylation following GSK3 inhibition.
In an attempt to determine if inhibition of GSK3 activity was ultimately leading to a change
in the levels of the putative kinases and phosphatases involved in the canonical AKT
activation pathway, we measured such levels by immunoblotting following RNA
interference targeting GSK3. We could not detect changes that could potentially explain
such a change in levels of AKT phosphorylation and activation. Moreover, the levels of
IGF1-R and EGFR, as well as their respective active and phosphorylated forms, remained
unchanged following GSK3 inhibition. We are aware though of the multiplicity of steps
involved in AKT activation, including other post-translational modifications and changes in
subcellular localization that can prime that molecule for migration to the plasma membrane
vicinities and its further interaction with PIP3, PDK1 and PDK2. For example, it has been
suggested that phosphorylation of Tyr315 and Tyr326 by Src is a step necessary for the full
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activation of AKT (Chen et al., 2001). Also, in a recent study, it has been demonstrated that,
in addition to phosphorylation, AKT undergoes lysine-63 chain ubiquitination. a process
mediated by the E3 ubiquitin ligase TRAF6 (TNF receptor associated Factor 6) (Yang et al.,
2009). K63 ubiquitination regulates protein trafficking and in this case it leads to increased
mobilization of AKT to the plasma membrane and increased phosphorylation on Thr308 and
Ser473. We have not investigated if other post-translational modifications of AKT such as
tyrosine phosphorylation or ubiquitination were affected by GSK3 inhibition. We have also
not yet determined if GSK3 inhibition ultimately leads to changes in AKT subcellular
localization. These all constitute future directions for the current study. A myriad of
molecules has been described in one cell system or another to interact with AKT and
interfere with its activation. The list of proteins that act as scaffold molecules allowing for
proper interaction of AKT with its kinases and also phosphatases is extensive and beyond
the scope of this discussion.
Reverse phase protein array technology has recently emerged as a tool that allows measuring
and profiling signaling pathways (Hennessy et al., 2011; Kornblau et al., 2009). By
assessing the expression and post-translational phosphorylation levels of proteins, RPPA
provides information that cannot be obtained by gene microarray analysis. Since the
previous investigation of the levels of kinases and phosphatases involved in the canonical
activation pathway of AKT provided no evidence of remarkable changes in that cell line, we
utilized this tool to uncover unexpected changes in signaling that could stem from GSK3
knockdown. In two different experiments in the MDA-MB-231 cell line, phosphorylated and
therefore active MAPK14 or p38 levels were elevated by at least 50%. This was independent
of growth factor stimulation.
While the p38 MAPK pathway has very important roles in the control of cellular responses
to different stresses, such as heat and osmotic shock as well as UV radiation, it can also
control the proliferation, differentiation, survival and migration of specific cell types. The
functions of p38 MAPK in cancer development are certainly complex, and while some cells
use this signaling pathway to antagonize cell proliferation, others subvert it to facilitate
proliferation, survival and invasion (Wagner and Nebreda, 2009).

There are 4 genes that

encode p38 MAPKs: MAPK14, MAPK11, MAPK12 and MAPK13 (which encode p38α,
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p38β, p38γ and p38δ, respectively). Most of the published literature on p38 MAPKs refers
to p38α, as it is the most abundant and ubiquitous of the p38 isoforms (Wagner and
Nebreda, 2009). The serine/threonine kinase p38α is activated by dual phosphorylation of its
Thr180 and Tyr182 (Raingeaud et al., 1995), typically after stimulation with proinflammatory cytokines and environmental stress. The classic activating kinases are the
MAP2Ks MKK3 and MKK6 (MKK4, a established activator of JNK, has also been
described to phosphorylate p38). Several different molecules can possibly function as
MAP3Ks (or kinases of MAP2Ks) for MKK3 and MKK6, including ASK1 (apoptosis
signal-regulating kinase 1), DLK1 (dual leucine zipper-bearing kinase 1) and TAK1 (TGFβactivated kinase 1) (Cuadrado and Nebreda, 2010). Once active, p38 MAPK targets
innumerous substrates, mostly kinases (such as MAPK-activated kinase 2 or MAPK2) and
transcription factors. Hsp27 is one of the targets of MAPK2 and its phosphorylation status
correlates with p38 activity. The stimulation and activation of p38 MAPK by growth factors
is typically poor.
The relationship between AKT and p38 has been described as antagonistic or as cooperative
at times, depending on the cell-context. For instance, cells expressing constitutively active
PI3K and AKT can have inhibited p38 activation (Berra et al., 1998), and the mechanism for
that might be the MEKK3 phosphorylation and inhibition of its activity, leading to downregulation of MKK3/6 and p38 activation (Gratton et al., 2001). In concordance with those
observations, another study investigated the interplay between AKT and p38, and
established a negative regulatory role for AKT in p38 activation through the
phosphorylation and consequent inhibition of ASK1, a known MAP3K (Liao and Hung,
2003). Other studies, relying mostly on work with chemical inhibitors, have ascribed a
positive regulatory role for p38 of AKT. In human neutrophils, for example, p38-dependent
active MAPK2 can function as PDK2 for AKT (Rane et al., 2001).
Interestingly though, there is some evidence that GSK3 and p38 participate directly in a
feedback loop in different cell systems. For instance, p38 has been implicated in the
phosphorylation and inhibition of GSK3β, by targeting its residue Thr390 (Al-Mulla et al.,
2011; Thornton et al., 2008). On the other hand, GSK3β can prevent p38 activation by
binding to MEKK4 (a possible MAP3K for p38) and preventing its dimerization. (Abell et
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al., 2007). In our study, the use of a p38 inhibitor in MDA-MB-231 cells was able to revert
completely the negative effects on AKT phosphorylation caused by GSK3 inhibition. This
validated the unexpected finding that stemmed from a broad proteomic analysis in that cell
line. However, it would be interesting not only to test this finding through inhibition of p38
using a different technique, but also to investigate its generalizability in other cell lines.
GSK3, like many other molecules that participate in the convergence of multiple signaling
axes, could, depending on the specificities of each tissue, the presence or lack of different
stresses or stimuli, and possibly even the duration of such events, promote different
outcomes in terms of cell growth, differentiation and proliferation. Interestingly, a recent
study has implicated GSK3β, but not GSK3α, as a kinase able to phosphorylate and inhibit
Rictor (essential for the kinase function of mTORC2) by targeting it at Ser1235, under ER
stress (Chen et al., 2011). This could explain the fall in AKT phosphorylation and activity
that is seen in situations that trigger ER stress, such as hyperosmolar states, and provides
emerging corroboratory evidence for a regulatory role that GSK3 possesses in AKT
activation.
Since GSK3 is rapidly becoming an attractive target for the treatment of multiple disorders,
considerable concern arises with interfering with the activity of a protein long regarded as a
tumor suppressor. In this study, we demonstrate that, in a variety of cell lines, GSK3 kinase
activity is necessary for the optimal phosphorylation and activation of AKT. These findings
add to an emerging number of studies that implicate GSK3 as a driver of tumorigenesis,
rather than a tumor suppressor. For example, ablation of GSK3β in colorectal cancer cells
activates p53-dependent apoptosis and antagonizes tumor growth (Ghosh and Altieri, 2005).
Specifically, inhibition of GSK3 activity can decrease the proliferation of human colon
cancer cells in rodents (Shakoori et al., 2007). GSK3 activity has also been linked to
proliferation of ovarian cancer cell lines, with the use of pharmacological inhibitors
suppressing cancer cell growth in vitro and in vivo (Cao et al., 2006). Similar findings have
been described in multiple myeloma (Cao et al., 2006) and chronic lymphocytic leukemia
cells (Ougolkov et al., 2007).
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CONCLUSIONS
GSK3 is required for optimal phosphorylation and activation of AKT in different malignant
cell lines as well as murine fibroblasts. The isoforms GSK3α and GSK3β have a redundant
role in regulating AKT activation. This effect is independent of the type of growth factor
utilized. It can also be observed in basal states, in HER2 overexpressing cell lines. The
kinase activity of GSK3 is required for this effect on AKT activation, since very specific
ATP-competitive inhibitors of GSK3 reproduce the effect seen with RNA interference
targeting GSK3. The levels of the putative kinases and phosphatases typically involved in
AKT activation and de-phosphorylation were found to be unchanged after GSK3 inhibition.
And so were the levels of the growth receptors. Analysis of a reverse phase protein array
screen in MDA-MB-231 cells revealed a greater than 50% increase in the levels of phosphop38, independent of growth factor stimulation. A pharmacological inhibitor of p38 rescued
completely AKT phosphorylation and activation in the presence of GSK3 inhibition,
suggesting this molecule plays an important role in this signaling event. GSK3 might well
constitute a desirable target for cancer treatment in the future.
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